Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9H4A4

UPID:
AMPB_HUMAN

ALTERNATIVE NAMES:
Arginine aminopeptidase; Arginyl aminopeptidase

ALTERNATIVE UPACC:
Q9H4A4; Q9BVM9; Q9H1D4; Q9NPT7

BACKGROUND:
Aminopeptidase B, identified by the UniProt accession Q9H4A4, is an exopeptidase with specificity for arginine and lysine residues. It is involved in the processing of several peptide substrates, including enkephalins and somatostatin, and plays a role in leukotriene metabolism.

THERAPEUTIC SIGNIFICANCE:
The exploration of Aminopeptidase B's function offers promising pathways for therapeutic intervention. Given its enzymatic activity in peptide processing and leukotriene metabolism, targeting this protein could lead to novel treatments for diseases characterized by abnormal peptide signaling or inflammatory responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.